{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sclc&page=5", "query": { "condition": "Sclc", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 4014, "total_pages": 402, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sclc&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sclc&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T15:11:05.199Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00921739", "title": "Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Small Cell Lung Cancer", "Thymoma", "Thymus Neoplasms" ], "interventions": [ { "name": "Esophageal sparing IMRT", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2009-09-11", "completion_date": "2016-11", "has_results": false, "last_update_posted_date": "2020-04-02", "last_synced_at": "2026-11-06T15:11:05.199Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00921739" }, { "nct_id": "NCT00535951", "title": "Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Mesothelioma" ], "interventions": [ { "name": "LBH589", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2007-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-11-06T15:11:05.199Z", "location_count": 4, "location_summary": "Fayetteville, Arkansas • Augusta, Georgia • Chicago, Illinois + 1 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00535951" }, { "nct_id": "NCT07586202", "title": "A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Amivantamab", "type": "DRUG" }, { "name": "Lazertinib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2026-07-28", "completion_date": "2028-04-03", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-06T15:11:05.199Z", "location_count": 6, "location_summary": "Duarte, California • Irvine, California • Stanford, California + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Portland", "state": "Oregon" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07586202" }, { "nct_id": "NCT04624204", "title": "Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab 200 mg", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab 400 mg", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab placebo (saline)", "type": "DRUG" }, { "name": "Olaparib 300 mg BID", "type": "DRUG" }, { "name": "Olaparib matching placebo", "type": "DRUG" }, { "name": "Etoposide 100 mg/m^2", "type": "DRUG" }, { "name": "Platinum, investigator's choice", "type": "DRUG" }, { "name": "Standard Thoracic Radiotherapy", "type": "RADIATION" }, { "name": "Prophylactic Cranial Irradiation (PCI)", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 672, "start_date": "2020-12-08", "completion_date": "2027-11-15", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-11-06T15:11:05.199Z", "location_count": 35, "location_summary": "Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04624204" }, { "nct_id": "NCT04330664", "title": "Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Metastatic Cancer", "Malignant Neoplastic Disease" ], "interventions": [ { "name": "MRTX849", "type": "DRUG" }, { "name": "TNO155", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2020-04-07", "completion_date": "2025-02-24", "has_results": false, "last_update_posted_date": "2025-04-04", "last_synced_at": "2026-11-06T15:11:05.199Z", "location_count": 17, "location_summary": "Los Angeles, California • Orange, California • Chicago, Illinois + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04330664" }, { "nct_id": "NCT03430063", "title": "A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Non-Small Cell Lung Carcinoma" ], "interventions": [ { "name": "SDREGN2810", "type": "DRUG" }, { "name": "SDREGN2810/ipi", "type": "DRUG" }, { "name": "HDREGN2810", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2018-05-29", "completion_date": "2021-10-27", "has_results": true, "last_update_posted_date": "2022-11-03", "last_synced_at": "2026-11-06T15:11:05.199Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Los Angeles, California • Whittier, California + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Scarborough", "state": "Maine" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03430063" }, { "nct_id": "NCT00376987", "title": "Zinc Supplements in Lowering Cadmium Levels in Smokers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Cervical Cancer", "Esophageal Cancer", "Gastric Cancer", "Head and Neck Cancer", "Kidney Cancer", "Leukemia", "Liver Cancer", "Lung Cancer", "Pancreatic Cancer", "Tobacco Use Disorder" ], "interventions": [ { "name": "zinc oxide", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "21 Years to 120 Years" }, "enrollment_count": 61, "start_date": "2003-12", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-11-06T15:11:05.199Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00376987" }, { "nct_id": "NCT02317016", "title": "Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Pharmacokinetic sampling - AZD9291", "type": "PROCEDURE" }, { "name": "AZD9291 tablet dosing", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Pharmacokinetic sampling - rosuvastatin", "type": "PROCEDURE" }, { "name": "Pharmacokinetic sampling - AZ5140 and AZ7550", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 44, "start_date": "2015-03-10", "completion_date": "2018-05-22", "has_results": true, "last_update_posted_date": "2018-07-31", "last_synced_at": "2026-11-06T15:11:05.199Z", "location_count": 1, "location_summary": "Fairfax, Virginia", "locations": [ { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02317016" }, { "nct_id": "NCT06048705", "title": "Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "GSK3901961", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adaptimmune", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2021-03-09", "completion_date": "2023-06-08", "has_results": true, "last_update_posted_date": "2024-11-13", "last_synced_at": "2026-11-06T15:11:05.199Z", "location_count": 12, "location_summary": "New Haven, Connecticut • Jacksonville, Florida • Tampa, Florida + 8 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06048705" }, { "nct_id": "NCT04198766", "title": "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Non-Small Cell Lung Cancer", "Head and Neck Cancer", "Melanoma", "Gastric Cancer", "Renal Cell Carcinoma", "Urothelial Carcinoma", "Resectable Non-Small-Cell Lung Cancer" ], "interventions": [ { "name": "INBRX-106 - Hexavalent OX40 agonist antibody", "type": "DRUG" }, { "name": "pembrolizumab 200 mg", "type": "DRUG" }, { "name": "pembrolizumab 400 mg", "type": "DRUG" }, { "name": "Carboplatin AUC-5", "type": "DRUG" }, { "name": "Carboplatin AUC-6", "type": "DRUG" }, { "name": "Pemetrexed 500 mg/m2", "type": "DRUG" }, { "name": "Cisplatin 75mg/m2", "type": "DRUG" }, { "name": "Paclitaxel 200mg/m2", "type": "DRUG" }, { "name": "Nab paclitaxel 100mg/m2", "type": "DRUG" }, { "name": "Gemcitabine (1000 mg/m2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inhibrx Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 340, "start_date": "2019-12-10", "completion_date": "2033-07", "has_results": false, "last_update_posted_date": "2026-11-06", "last_synced_at": "2026-11-06T15:11:05.199Z", "location_count": 39, "location_summary": "Duarte, California • Glendale, California • La Jolla, California + 32 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04198766" } ] }